• The Precision Peptide Company received about 20,000 BPC-157 transdermal patches, marking its shift from testing to commercialization.
• Initial commercial release is planned through the company’s website.
• Each patch is formulated to deliver 2 mg of BPC-157; third-party testing showed 95.5% purity and a 2.02 mg dose.
• The patches were manufactured in the U.S. and independently tested by a U.S. analytical laboratory.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Precision Peptide Company Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607140700NEWSFILECNPR____20260714_305067_1) on July 14, 2026, and is solely responsible for the information contained therein.